Indaptus Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Indaptus Therapeutics, Inc. (INDP) reported Earnings Per Share, Basic and Diluted of -$1.89 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-21.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-03-21
- Indaptus Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.39.
- Indaptus Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.81.
- Indaptus Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$5.53.
- Indaptus Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.40.
- Indaptus Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.89.
- Indaptus Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.84.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2023-03-17 | -$1.06 derived: net income ÷ weighted average shares · filed 2023-03-17 | -$1.71 derived: net income ÷ weighted average shares · filed 2023-03-17 | -$1.89 10-K · filed 2022-03-21 |
| 2021-09-30 | -$0.81 10-Q · filed 2021-11-15 | -$1.86 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.67 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$5.53 10-Q · filed 2021-08-16 | -$9.46 10-Q · filed 2021-08-16 | ||
| 2020-12-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$1.19 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$2.33 derived: net income ÷ weighted average shares · filed 2022-03-21 | -$1.84 10-K · filed 2022-03-21 |
| 2020-09-30 | -$0.79 10-Q · filed 2021-11-15 | -$2.32 derived: net income ÷ weighted average shares · filed 2021-11-15 | -$1.45 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$3.66 10-Q · filed 2021-08-16 | -$9.65 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |